Corporate Information

BUSINESS FOCUS & GROWTH STRATEGY

Zim focuses on multiple business aspects & multi-pronged growth strategy for sustained progress.

GROWTH INITIATIVES

IN CONTINUE NDDS: AS CORE OFFERING

Focus on developing new delivery solutions for generic products which

ehacedlife

Enhance product life cycle

patience convenience

Increase patient convenience

improve_adherence

Improved adherence in treatement

improve_adherence

Improved adherence in treatement


with priority on certain therapeutic segments.

COMMERCIALISE OTF PLATFORMS

Alternate drug delivery solution for generic pharmaceutical & nutraceutical products (prescription & OTC)

Step up direct marketing:

ehacedlife

Hire senior marketing professionals for developing marketing partnerships in finished formulations and semi-finished products across RoW markets.

patience convenience

Invest in product registration & marketing partnerships that allow ZIM to capture value of brands and better margins.


Invest in R&D with focus on entering developed markets

ehacedlife

Equipment, team, studies, processes & systems.

patience convenience

Facilities to develop a pipeline of products valuable to business partners & patients across markets (co-development & own new product alternatives) with specific focus on entering developed markets.


ENHANCE CAPACITY AND FLEXIBILITY IN OPERATIONS

Add small batch manufacturing (SBM) facilities for promoting the formulations business & supporting clients across markets with small but high value order quantities including technology transfer from R&D.

STRENGTHTEN R&D CENTER AND INVEST IN PRODUCT DEVELOPEMENT

Focus on developing new delivery solutions for generic products which:

ehacedlife

Continue strengthening R&D capabilities – Increase investment in R&D as % of sales.

patience convenience

Acquire scientists, formulators, analysts & add higher end scientific equipment to the existing R&D centre.

patience convenience

Invest in various pilot, pivotal stability and BE studies (own & under co-development) to enhance development process, audit trails, dossier readiness, filings & registrations.

patience convenience

Partnering with non-infringing API producers for developing products to be launched in EM.


NEW R&D CENTER FOR DEVELOPED MARKETS
ehacedlife

Hire experienced R&D professionals to lead product development, various studies, dossier readiness, filings, registration and launch of products in U.S.A / Developed Markets; with expertise for product registrations from U.S.A FDA, MHRA UK, ANVISA, etc.

patience convenience

The OTF R&D Centre to initiate independent contract research operations for other pharmaceutical companies in regulated markets.

patience convenience

Invest in pilot, pivotal and bio-equivalence studies (Under Co-Development).

patience convenience

R&D centre to eventually launch products in Developed Markets – key target being USA (prescription and OTC products) with immediate focus being on “emerging and RoW markets”.

patience convenience

New Drug Delivery Platforms (MUPS, Patches etc.) to be developed at this R&D centre.


NEW REGISTRATIONS

Invest in team and processes for development of dossiers and product registration/filings across markets.

PRE FORMULATED INTERMEDIATES (PFI)
ehacedlife

Strengthen core PFI business with focus on developing a pipeline of high margin products.

patience convenience

Enter into local marketing tie-ups and new partnerships in new geographies like LATAM, CIS and MENA


DIFFERENTIATED FORMULATIONS
ehacedlife

ZIM ventured into Sri Lanka directly for differentiated formulations in FY 2011.

patience convenience

Products were jointly developed in consultation with Sri Lankan partners & supplied in finished dosage form, including ready to market packaging and the registrations of the product with the partner. The business in Sri Lanka grew 12x over the last 6 years from INR 10 Million in FY11 to INR 127 Million in FY17 with a CAGR of over 50%.

ehacedlife

ZIM plans to replicate the Sri Lankan model in other regions and introduce high margin differentiated generic formulations in RoW and Emerging Markets – MENA, SA, SEA, CIS & LATAM.

patience convenience

Enter into marketing joint venture arrangements, partnerships, authorisations for specific markets to capture more of the value chain in terms of brand registrations and improved margins.


ORALTHIN FILMS (OTF)
ehacedlife

Focus on new product development and product life extensions for original product manufacturers (OPMs).

patience convenience

Enter into long term licensing agreements with OPM and other players to co-develop their existing products in OTF format.

ehacedlife

Plans to enter into developed markets (US, EU, JAPAN) in partnership with OPMs over time.

patience convenience

Register the OTF product in RoW and emerging markets under its brand and market through partnership with local players.


NEW PELLETS AND GRANUALES MANUFACTURING FACILITY

Set-up dedicated small batch manufacturing (SBM) facility for manufacturing pellets, tablets & granules to bring about.

ehacedlife

Flexibility in manufacturing for pre-formulation and formulation for exports and,

patience convenience

Unlock capacity constraint in existing plant.


ENHANCING QUALITY ASSURANCE (QA) AND QUALITY CONTROL (QC)
ehacedlife

Internal reorganisation & upgrading of certain facilities for improved audit and compliance.

patience convenience

Investment in equipment and more experienced manpower.

patience convenience

Invest in ERP for integrated software that covers operations & financial processes in line with requirements of developed markets.


COMPANY LEADERSHIP

Dr. Anwar S. Daud

(M.Pharm, PHD)
Chairman and Managing Director

Dr. Anwar Daud, PhD. (Pharmaceutical Sciences), M. Pharm. (Medicinal Chemistry) from
Nagpur University (1983), promoted ZIM in 1989.

Read More

MANAGEMENT COMMITTEE

Mr. Zulfiquar Kamal(B.Com, FCA)

Director - Finance

Mr. Zulfiquar Kamal is a chartered accountant and has been associated with the company for over 25 years.

Read More

Mr. Prakash Sapkal(B.Pharm. MBA)

Director-Operations

Mr. Prakash Sapkal is a Pharmacy graduate with post-graduation in Business Administration and has been associated with the Company for 24 years.

Read More

Mr. Vijay Fudke(B.Pharm. DMP)

Senior Vice President – Technical Services

Mr Vijay Fudke is a pharmacy graduate with an association of more than 20 years with ZIM.

Read More

Mr. Niraj Dhadiwal (B.Pharm. DBM)

Director - Business Development

Mr. Niraj Dhadiwal is a pharmacy graduate with a diploma in business management and has been with the company for nearly three decades.

Read More

Mr. Riaz Kamal (B.Sc. AIC)

Director - Administration

Mr Riaz Kamal has been associated with the company since inception.

Read More

Mr. Pradeep Kataria (M.Pharm)

Senior Vice President – Operations

Mr Pradeep Kataria is a postgraduate in pharmacy with an association of more than 21 years with the organization.

Read More

OUR PRESENCE

Current Presence

Target Markets

FINANCIALS

Over the last 4 years, high margin business (>50% gross margin) has seen a CAGR of 20%
(growing 1.7x) compared to a drop of 17% CAGR in the low margin business during the same period. The strategy for improving margins and consequently better return from capital employed has been driven primarily on account of:

stock-up

Focused marketing efforts on direct exports of PFI.

formulation

Formulation Products.

stock-down

Reducing low margin deemed exports business-particularly from Africa.

bidding

Direct bidding for higher margin products in.

tender

Government tenders vs. bidding through third parties.

commmercialisation

‘Commercialization’ of the OTF range of products.

STANDALONE HALF YEARLY INCOME STATEMENTS FY 2018

INR in Millions | Figures are as per Ind AS

STANDALONE YEARLY INCOME STATEMENTS

INR in Millions | Figures are as per Ind AS

STANDALONE YEARLY STATEMENTS OF FINANCIAL POSITION

INR in Millions | Figures are as per Ind AS

INVESTOR REPORTS & PRESENTATIONS

OUR CORPORATE PRESENTATIONS

  • ANNUAL RESULTS
  • QUARTERLY RESULTS
  • ANNUAL REPORTS
  • SHAREHOLDING PATTERN
  • POLICIES
  • STATUTORY COMMUNICATIONS
ANNUAL RESULTS

ANNUAL FINANCIAL RESULTS

QUARTERLY RESULTS

QUARTERLY FINANCIAL RESULTS

Our Quarterly Financials

ANNUAL REPORTS

ANNUAL REPORTS

We are pleased to present to you ZIM Laboratories Limited Annual Reports.

SHAREHOLDING PATTERN

SHAREHOLDING PATTERN

Our Shareholding Patterns

Share Holding

POLICIES

POLICIES

Our Policies

STATUTORY COMMUNICATIONS

STATUTORY COMMUNICATIONS

  • 2018
2018

INVESTOR CONTACT

MR. PIYUSH NIKHADE

Sadoday Gyan (Ground Floor)

Opp. NADT, Nelson Square,

Nagpur – 440013

 cs@zimlab.in  0712-2588070